
NORWAY - Algeta raises NOK 250m in IPO
Algeta, Norwegian Cancer therepeutics successfully closed its IPO at a gross proceeds (before over-allotment) of NOK 250m. The offering was more than twice over-subscribed and was priced in the upper half of NOK 47 per share. The offering took place in conjunction with Algeta's listing on the Oslo stock exchange, and the shares are expected to begin to trade today (27 March).
Latest News
PE-backed Helgstrand Dressage merges with Ludger Beerbaum Stables
Waterland-backed Danish company Helgstrand Dressage has acquired and merged with equestrian show jumping business Ludger Beerbaum Stables.
Zefyr Invest acquires Bramidan from Blue Equity
GP is deploying equity from Zefyr Invest III, and Bramidan is its third acquisition from the vehicle
Merieux Equity buys Plantex
GP invests in the company via Mérieux Participations 3, which closed on €377m in January 2020
Carlyle-backed Hurst Point acquires Hawksmoor
Hurst Point Group was established in 2019 to facilitate investment by Carlyle in UK wealth management